幸运飞艇计划

N-terminal acetyltransferases (NATs) catalyse the聽N-terminal acetylation of a majority of human proteins.聽The NAT-enzymes have been linked to cancer development and progression, and detailed molecular knowledge is essential for developing specific聽compounds to target the NATs for potential cancer chemotherapy.

Now, researchers at the NAT-group, MBI, 幸运飞艇计划, Department of Surgery, HUS,聽and the group of聽Professor at The Scripps Research Institute Florida, have developed the first specific NAT-inhibitors. These inhibitors are able to discriminate between different NAT-enzymes in vitro and are now being further developed for in vivo use ().

Very recently, similar inhibitors were used by Professor (The Wistar Institute) to solve the first structure of a NAT-complex. The structure of NatA, the major NAT-complex in eukaryotes, revealed the molecular basis for N-terminal acetylation by a NAT and defined interesting aspects on how the catalytic subunit of the complex聽is modulated by the auxiliary subunit (). 聽